New weekly diabetes drug takes on popular rival in 546-patient trial
NCT ID NCT07156539
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 28 times
Summary
This study tests a new once-weekly injection called HS-20094 against an existing drug, dulaglutide, for people with type 2 diabetes whose blood sugar is not well controlled with metformin alone or metformin plus another diabetes pill. About 546 adults will receive one of the two weekly shots for up to 52 weeks. The main goal is to see if HS-20094 lowers blood sugar (HbA1c) as well as or better than dulaglutide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shandong Provincial Hospital
Jinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University General Hospital (Zhu Xianyi Memorial Hospital)
Tianjin, Tianjn, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.